NCT05326451 Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease
| NCT ID | NCT05326451 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center, Houston |
| Condition | Huntington Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2023-06-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2023-06-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess feasibility, acceptability, and safety of providing transcranial direct current stimulation( tDCS) to Huntingtons Disease (HD) patients in the early to middle stages and to assess the efficacy of tDCS for HD-related behavioral, cognitive and other symptoms
Eligibility Criteria
Participant: Inclusion Criteria: * confirmed HD mutation carriers and/or established family history alongside typical symptoms (i.e. chorea) of HD; * early (stages 1 and 2) or moderate (stage 3) stages according to Shoulson-Fahn * exhibit mild to moderate behavioral symptoms defined by severity scores in the PBA-S between 1 and 3 for any of the evaluated symptoms and no symptoms with a severity score of 4 * stable doses of medications for at least one month * Have a caregiver willing to be present during tDCS sessions and answer questionnaires. Exclusion Criteria: * unstable medical conditions * history of epilepsy * metallic objects in the brain * Have a caregiver willing to be present during tDCS sessions and answer questionnaires. * clinical diagnosis of major cognitive disorder or dementia * Have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4 or type 5 based on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening * simultaneous participation in other clinical trial * Individuals determined to be incapable of consent per past medical history or via assessment by the study staff at time of consent. Caregiver: Inclusion Criteria: -willingness to participate in the study Exclusion Criteria: -motor/cognitive symptoms related to Alzheimer's disease or Huntington's disease that might impair the ability to assist the participant during the research study.
Contact & Investigator
Erin Stimming, MD
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center, Houston
Frequently Asked Questions
Who can join the NCT05326451 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Huntington Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05326451 currently recruiting?
Yes, NCT05326451 is actively recruiting participants. Contact the research team at Erin.E.Furr@uth.tmc.edu for enrollment information.
Where is the NCT05326451 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT05326451 clinical trial?
NCT05326451 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Erin Stimming, MD at The University of Texas Health Science Center, Houston. The trial plans to enroll 10 participants.